Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma
Corresponding Author
Till Milde
Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg, Germany
Clinical Cooperation Unit Pediatric Oncology G340, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, GermanySearch for more papers by this authorStefan Pfister
Division of Molecular Genetics (B060), German Cancer Research Center, Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
Search for more papers by this authorAndrey Korshunov
Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
Clinical Cooperation Unit Neuropathology (G380), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorHedwig E. Deubzer
Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
Search for more papers by this authorIna Oehme
Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorAurélie Ernst
Division of Molecular Genetics (B060), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorAnna Starzinski-Powitz
Institute for Cell Biology and Neuroscience, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorAngelika Seitz
Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany
Search for more papers by this authorPeter Lichter
Division of Molecular Genetics (B060), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorAndreas von Deimling
Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
Clinical Cooperation Unit Neuropathology (G380), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorOlaf Witt
Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
Search for more papers by this authorCorresponding Author
Till Milde
Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg, Germany
Clinical Cooperation Unit Pediatric Oncology G340, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, GermanySearch for more papers by this authorStefan Pfister
Division of Molecular Genetics (B060), German Cancer Research Center, Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
Search for more papers by this authorAndrey Korshunov
Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
Clinical Cooperation Unit Neuropathology (G380), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorHedwig E. Deubzer
Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
Search for more papers by this authorIna Oehme
Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorAurélie Ernst
Division of Molecular Genetics (B060), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorAnna Starzinski-Powitz
Institute for Cell Biology and Neuroscience, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorAngelika Seitz
Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany
Search for more papers by this authorPeter Lichter
Division of Molecular Genetics (B060), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorAndreas von Deimling
Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
Clinical Cooperation Unit Neuropathology (G380), German Cancer Research Center, Heidelberg, Germany
Search for more papers by this authorOlaf Witt
Clinical Cooperation Unit Pediatric Oncology (G340), German Cancer Research Center, Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, University Hospital Heidelberg, Heidelberg, Germany
Search for more papers by this authorAbstract
Nonresectable ependymomas are associated with poor prognosis despite intensive radiochemotherapy and radiation. The molecular pathogenesis of ependymoma initiation and progression is largely unknown. We here present a case of therapy-refractory, progressive ependymoma with cerebrospinal as well as extraneural metastases, which allowed us for the first time to follow the stepwise accumulation of chromosome aberrations during disease progression. Genome-wide DNA copy-number analysis showed sequential deletions on chromosomes 1, 9, and 14 as well as a homozygous deletion of the CDKN2A locus, underscoring its role in tumor progression. Gradual loss at 1p36 was associated with loss of protein expression of the putative tumor suppressor gene AJAP1/SHREW1. In summary, this is the first report on acquired genomic aberrations in ependymoma over time pointing to novel candidate tumor suppressor genes. This analysis provides molecular insights into the chronology of genetic events in this case from initial localized tumor to widespread metastasized disease. © 2008 Wiley-Liss, Inc.
REFERENCES
- Agaoglu FY,Ayan I,Dizdar Y,Kebudi R,Gorgun O,Darendeliler E. 2005. Ependymal tumors in childhood. Pediatr Blood Cancer 45: 298–303.
- Antic D,Lu N,Keene JD. 1999. ELAV tumor antigen, Hel-N1, increases translation of neurofilament M mRNA and induces formation of neurites in human teratocarcinoma cells. Genes Dev 13: 449–461.
- Bharti S,Handrow-Metzmacher H,Zickenheiner S,Zeitvogel A,Baumann R,Starzinski-Powitz A. 2004. Novel membrane protein shrew-1 targets to cadherin-mediated junctions in polarized epithelial cells. Mol Biol Cell 15: 397–406.
- Cairns P,Okami K,King P,Bonacum J,Ahrendt S,Wu L,Mao L,Jen J,Sidransky D. 1997. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res 57: 5356–5359.
- Dyer S,Prebble E,Davison V,Davies P,Ramani P,Ellison D,Grundy R. 2002. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 161: 2133–2141.
- Ebert C,von Haken M,Meyer-Puttlitz B,Wiestler OD,Reifenberger G,Pietsch T,von Deimling A. 1999. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 155: 627–632.
- Fouladi M,Helton K,Dalton J,Gilger E,Gajjar A,Merchant T,Kun L,Newsham I,Burger P,FullerC 2003. Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer 98: 2232–2244
- Gao FB,Keene JD. 1996. Hel-N1/Hel-N2 proteins are bound to poly(A)+ mRNA in granular RNP structures and are implicated in neuronal differentiation. J Cell Sci 109(Part 3): 579–589.
- Grill J,Avet-Loiseau H,Lellouch-Tubiana A,Sevenet N,Terrier-Lacombe MJ,Venuat AM,Doz F,Sainte-Rose C,Kalifa C,Vassal G. 2002. Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genet Cytogenet 136: 121–125.
- Gurney JG,Smith MA,Bunin GR. 1999. CNS and miscellaneous intracranial and intraspinal neoplasms, ICCC III. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program, NIH Pub. No. 99-4649.
- Guyotat J,Signorelli F,Desme S,Frappaz D,Madarassy G,Montange MF,Jouvet A,Bret P. 2002. Intracranial ependymomas in adult patients: Analyses of prognostic factors. J Neurooncol 60: 255–268.
- Hirose Y,Aldape K,Bollen A,James CD,Brat D,Lamborn K,Berger M,Feuerstein BG. 2001. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 158: 1137–1143.
- Huang B,Starostik P,Schraut H,Krauss J,Sorensen N,Roggendorf W. 2003. Human ependymomas reveal frequent deletions on chromosomes 6 and 9. Acta Neuropathol 106: 357–362.
- Kaatsch P,Spix C. 2008. Annual Report 2006 / 2007 (1980–2006). German Childhood Cancer Registry at the Institute for Medical Biostatistics, Epidemiology and Informatics (IMBEI). Mainz, Germany: Johannes Gutenberg University Mainz.
- Korshunov A,Golanov A,Timirgaz V. 2000. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. J Neurol Sci 177: 72–82.
- Korshunov A,Golanov A,Sycheva R,Timirgaz V. 2004. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: An analysis of 258 patients. Cancer 100: 1230–1237.
- Louis DN,Ohgaki H,Wiestler OD,Cavenee WK,Burger PC,Jouvet A,Scheithauer BW,Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97–109.
- McDonald JM,Dunlap S,Cogdell D,Dunmire V,Wei Q,Starzinski-Powitz A,Sawaya R,Bruner J,Fuller GN,Aldape K,Zhang W. 2006. The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biol Ther 5: 300–304.
- Mendrzyk F,Korshunov A,Benner A,Toedt G,Pfister S,Radlwimmer B,Lichter P. 2006. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12: 2070–2079.
- Modena P,Lualdi E,Facchinetti F,Veltman J,Reid JF,Minardi S,Janssen I,Giangaspero F,Forni M,Finocchiaro G,Genitori L,Giordano F,Riccardi R,Schoenmakers EF,Massimino M,Sozzi G. 2006. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 24: 5223–5233.
- Oppenheim JS,Strauss RC,Mormino J,Sachdev VP,Rothman AS. 1994. Ependymomas of the third ventricle. Neurosurgery 34: 350–352; discussion 352–353.
-
Reardon DA,Entrekin RE,Sublett J,Ragsdale S,Li H,Boyett J,Kepner JL,Look AT.
1999.
Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma.
Genes Chromosomes Cancer
24:
230–237.
10.1002/(SICI)1098-2264(199903)24:3<230::AID-GCC8>3.0.CO;2-C CAS PubMed Web of Science® Google Scholar
- Reni M,Brandes AA,Vavassori V,Cavallo G,Casagrande F,Vastola F,Magli A,Franzin A,Basso U,Villa E. 2004. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 100: 1221–1229.
- Rezai AR,Woo HH,Lee M,Cohen H,Zagzag D,Epstein FJ. 1996. Disseminated ependymomas of the central nervous system. J Neurosurg 85: 618–624.
- Rickert CH,Korshunov A,Paulus W. 2006. Chromosomal imbalances in clear cell ependymomas. Mod Pathol 19: 958–962.
- Rushing EJ,Brown DF,Hladik CL,Risser RC,Mickey BE,White CL,III. 1998. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype. Mod Pathol 11: 464–470.
- Schreiner A,Ruonala M,Jakob V,Suthaus J,Boles E,Wouters F,Starzinski-Powitz A. 2007. Junction protein shrew-1 influences cell invasion and interacts with invasion-promoting protein CD147. Mol Biol Cell 18: 1272–1281.
- Shu HK,Sall WF,Maity A,Tochner ZA,Janss AJ,Belasco JB,Rorke-Adams LB,Phillips PC,Sutton LN,Fisher MJ. 2007. Childhood intracranial ependymoma: Twenty-year experience from a single institution. Cancer 110: 432–441.
-
Solinas-Toldo S,Lampel S,Stilgenbauer S,Nickolenko J,Benner A,Dohner H,Cremer T,Lichter P.
1997.
Matrix-based comparative genomic hybridization: Biochips to screen for genomic imbalances.
Genes Chromosomes Cancer
20:
399–407.
10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- Suzuki S,Oka H,Kawano N,Tanaka S,Utsuki S,Fujii K. 2001. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas. Brain Tumor Pathol 18: 151–154.
- Taylor MD,Poppleton H,Fuller C,Su X,Liu Y,Jensen P,Magdaleno S,Dalton J,Calabrese C,Board J,Macdonald T,Rutka J,Guha A,Gajjar A,Curran T,Gilbertson RJ. 2005. Radial glia cells are candidate stem cells of ependymoma. Cancer Cells 8: 323–335.
- Timmermann B,Kortmann RD,Kuhl J,Meisner C,Slavc I,Pietsch T,Bamberg M. 2000. Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: Results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys 46: 287–295.
- Varan A,Sari N,Akalan N,Soylemezoglu F,Akyuz C,Kutluk T,Buyukpamukcu M. 2006. Extraneural metastasis in intracranial tumors in children: The experience of a single center. J Neurooncol 79: 187–190.
- Verstegen MJ,Leenstra DT,Ijlst-Keizers H,Bosch DA. 2002. Proliferation- and apoptosis-related proteins in intracranial ependymomas: An immunohistochemical analysis. J Neurooncol 56: 21–28.
- Wong KK,Tsang YT,Chang YM,Su J,Di Francesco AM,Meco D,Riccardi R,Perlaky L,Dauser RC,Adesina A,Bhattacharjee M,Chintagumpala M,Lau CC. 2006. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res 66: 11172–11178.
- Yano M,Okano HJ,Okano H. 2005. Involvement of Hu and heterogeneous nuclear ribonucleoprotein K in neuronal differentiation through p21 mRNA post-transcriptional regulation. J Biol Chem 280: 12690–12699.
- Zamecnik J,Snuderl M,Eckschlager T,Chanova M,Hladikova M,Tichy M,Kodet R. 2003. Pediatric intracranial ependymomas: Prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol 16: 980–991.
- Zielinski B,Gratias S,Toedt G,Mendrzyk F,Stange DE,Radlwimmer B,Lohmann DR,Lichter P. 2005. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 43: 294–301.
